USE OF INTRAVENOUS FK506 TO TREAT ACUTE REJECTION IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS ON MAINTENANCE ORAL FK506
- 1 March 1997
- journal article
- case report
- Published by Wolters Kluwer Health in Transplantation
- Vol. 63 (5) , 785-788
- https://doi.org/10.1097/00007890-199703150-00030
Abstract
Most recipients of simultaneous pancreas-kidney transplants experience acute rejection in the early postoperative course. We report our experience with four recipients of simultaneous pancreas-kidney transplants with acute rejection who were effectively treated with the combination of intravenous and oral FK506 therapy. This spared these patients an extra course of monoclonal or polyclonal antibody.Keywords
This publication has 8 references indexed in Scilit:
- DEPLETION OF THE MATURE CD4+8- THYMOCYTE SUBSET BY FK506 ANALOGS CORRELATES WITH THEIR IMMUNOSUPPRESSIVE AND CALCINEURIN INHIBITORY ACTIVITIESTransplantation, 1996
- A MULTICENTER ANALYSIS OF THE FIRST EXPERIENCE WITH FK506 FOR INDUCTION AND RESCUE THERAPY AFTER PANCREAS TRANSPLANTATION1Transplantation, 1996
- NORMAL PANCREAS ALLOGRAFT FUNCTION FOLLOWING SIMULTANEOUS PANCREAS KIDNEY TRANSPLANTATION AFTER RESCUE THERAPY WITH TACROLIMUS (FK506)Transplantation, 1995
- THE RELATIONSHIP OF GLUCOSE DISAPPEARANCE RATE (kG) TO ACUTE PANCREAS ALLOGRAFT REJECTIONTransplantation, 1994
- New Immunosuppressive Drugs: Mechanistic Insights and Potential Therapeutic AdvancesImmunological Reviews, 1993
- Metabolic Effects of Cyclosporin A and FK 506 in Liver Transplant RecipientsDiabetes, 1993
- TacrolimusDrugs, 1993
- Experience With 100 Consecutive Simultaneous Kidney-Pancreas Transplants With Bladder DrainageAnnals of Surgery, 1991